Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.

Zhanhong Chen Tian Sun Zi-Yan Yang Yabing Zheng Ruoying Yu Xue Wu Junrong Yan Yang W Shao Xiying Shao Wen-Ming Cao Xiao-Jia Wang

Published in: Molecular genetics & genomic medicine (2019)

In summary, ctDNA monitoring, particularly longitudinal analyses, provides valuable insights into the assessment of targeted therapy efficacy and gene alterations underlying trastuzumab resistance and chemotherapy resistance in HER2+ and HER2- BC patients, respectively.

Keyphrases

circulating tumor
cell free
circulating tumor cells
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
copy number
prognostic factors
gene expression
radiation therapy
epidermal growth factor receptor
locally advanced
combination therapy
dna methylation
patient reported outcomes